CY1107974T1 - Παραγωγα κινολινης και κιναζολινης εχοντα συναφεια προς τους υποδοχεις τυπου 5ht1 - Google Patents

Παραγωγα κινολινης και κιναζολινης εχοντα συναφεια προς τους υποδοχεις τυπου 5ht1

Info

Publication number
CY1107974T1
CY1107974T1 CY20081100555T CY081100555T CY1107974T1 CY 1107974 T1 CY1107974 T1 CY 1107974T1 CY 20081100555 T CY20081100555 T CY 20081100555T CY 081100555 T CY081100555 T CY 081100555T CY 1107974 T1 CY1107974 T1 CY 1107974T1
Authority
CY
Cyprus
Prior art keywords
kinazolin
kinolin
receptors
derivatives related
derivatives
Prior art date
Application number
CY20081100555T
Other languages
English (en)
Inventor
Markus Bergauer
Barbara Bertani
Matteo Biagetti
Steven Mark Bromidge
Alessandro Falchi
Colin Philip Leslie
Giancarlo Merlo
Domenica Antonia Pizzi
Marilisa Rinaldi
Luigi Piero Stasi
Jessica Tibasco
Antonio Kuok Keong Vong
Simon Edward Ward
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of CY1107974T1 publication Critical patent/CY1107974T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)

Abstract

Παρέχονται ενώσεις τύπου (Ι) και φαρμακευτικά αποδεκτά άλατά τους: όπου τα R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 και q έχουν τις έννοιες που ορίζονται στην περιγραφή. Αποκαλυπτονται επίσης μέθοδοι παρασκευής και χρήσεις τους στη θεραπεία, ιδιαίτερα για διαταραχές του ΚΝΣ.
CY20081100555T 2003-07-18 2008-05-29 Παραγωγα κινολινης και κιναζολινης εχοντα συναφεια προς τους υποδοχεις τυπου 5ht1 CY1107974T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316915.8A GB0316915D0 (en) 2003-07-18 2003-07-18 Compounds
EP04763307A EP1646613B1 (en) 2003-07-18 2004-07-15 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors

Publications (1)

Publication Number Publication Date
CY1107974T1 true CY1107974T1 (el) 2013-09-04

Family

ID=27764115

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100555T CY1107974T1 (el) 2003-07-18 2008-05-29 Παραγωγα κινολινης και κιναζολινης εχοντα συναφεια προς τους υποδοχεις τυπου 5ht1

Country Status (29)

Country Link
US (5) US7279481B2 (el)
EP (3) EP1646613B1 (el)
JP (1) JP2006528146A (el)
KR (1) KR20060041242A (el)
CN (1) CN100441571C (el)
AR (1) AR046394A1 (el)
AT (2) ATE448205T1 (el)
AU (1) AU2004263268B2 (el)
BR (1) BRPI0412695A (el)
CA (1) CA2532452A1 (el)
CY (1) CY1107974T1 (el)
DE (2) DE602004012564T2 (el)
DK (1) DK1646613T3 (el)
ES (2) ES2302543T3 (el)
GB (1) GB0316915D0 (el)
HK (1) HK1089438A1 (el)
HR (1) HRP20080226T3 (el)
IL (1) IL173036A0 (el)
IS (1) IS2744B (el)
MA (1) MA27926A1 (el)
MX (1) MXPA06000716A (el)
NO (1) NO20060774L (el)
NZ (1) NZ544586A (el)
PL (1) PL1646613T3 (el)
PT (1) PT1646613E (el)
RU (1) RU2402533C2 (el)
SI (1) SI1646613T1 (el)
TW (1) TW200521115A (el)
WO (1) WO2005014552A1 (el)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US8110595B2 (en) * 2004-06-17 2012-02-07 Cytokinetics, Inc. Ureas and their use in the treatment of heart failure
KR100817538B1 (ko) * 2006-07-05 2008-03-27 한국화학연구원 신규 치환된―１ｈ―퀴나졸린―２,４―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물
CA2673481A1 (en) * 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
US20100076006A1 (en) * 2007-01-31 2010-03-25 University Of Virginia Patent Foundation Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
ATE499099T1 (de) 2007-07-19 2011-03-15 Esteve Labor Dr Substituierte tetrahydro- chinolinsulfonamidverbindungen, ihre herstellung und ihre verwendung als medikamente
US20110065628A1 (en) * 2007-08-27 2011-03-17 University Of Virginia Patent Foundation Medication Combinations for the Treatment of Alcoholism and Drug Addiction
WO2009108837A2 (en) * 2008-02-28 2009-09-03 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
WO2009132202A2 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
ES2358718T3 (es) * 2008-05-06 2011-05-13 Biedermann Motech Gmbh Implante en forma de varilla, en concreto para la estabilización dinámica de la columna vertebral.
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
EP2308850A1 (en) * 2009-10-06 2011-04-13 Laboratorios Del. Dr. Esteve, S.A. Heterocycyl-substituted-alkylamino phenyl derivatives, their preparation and use as medicaments
EP2801625B1 (en) 2010-07-02 2017-11-01 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
BR112014002939A2 (pt) * 2011-08-09 2017-03-01 Takeda Pharmaceuticals Co composto, medicamento, método para profilaxia ou tratamento de doença, a doença sendo esquizofrenia, alzheimer, parkinson ou huntington, uso do composto, e, método para inibir o lsd1
EA027743B1 (ru) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
AU2013259551B2 (en) * 2012-05-09 2017-11-02 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN103508927A (zh) * 2012-06-25 2014-01-15 天津药物研究院 一种2-甲磺酰氨基二苯醚的制备方法
EP2907802B1 (en) 2012-10-12 2019-08-07 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP3072884B1 (en) 2013-11-20 2020-01-01 Sanwa Kagaku Kenkyusho Co., Ltd. 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purposes
TN2016000418A1 (en) 2014-04-11 2018-04-04 Takeda Pharmaceuticals Co Cyclopropanamine compound and use thereof.
WO2016075314A1 (fr) 2014-11-13 2016-05-19 Institut National De La Recherche Agronomique Identification de facteurs de transcription de yarrowia lipolytica affectant la production de proteines
FR3028527A1 (fr) 2014-11-13 2016-05-20 Pivert Identification de facteurs de transcription de yarrowia lipolytica
EP3395351A1 (en) 2014-12-23 2018-10-31 4D Pharma Research Limited Immune modulation
JP6427278B2 (ja) 2014-12-23 2018-11-21 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ ｐｉｒｉｎポリペプチド及び免疫モジュレーション
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3650033T (pt) 2015-06-15 2022-05-25 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
BR112017025005A2 (pt) 2015-06-15 2018-08-07 4D Pharma Research Limited composições compreendendo cepas baterianas
CN107847529B (zh) 2015-06-15 2022-05-03 4D制药研究有限公司 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41013A (fr) 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EA035949B1 (ru) 2016-03-04 2020-09-04 4Д ФАРМА ПиЭлСи Применение композиции, содержащей бактериальный штамм вида blautia hydrogenotrophica, и способ лечения или предотвращения висцеральной гиперчувствительности
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
MA48939B1 (fr) 2017-05-22 2021-06-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
LT3638271T (lt) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozicijos, apimančios bakterines padermes
MD3600364T2 (ro) 2017-06-14 2020-12-31 4D Pharma Res Ltd Compoziții care conţin tulpină bacteriană din genul Megasphaera și utilizări ale acestora
HUE053488T2 (hu) 2017-06-14 2021-06-28 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
CN108047143A (zh) * 2017-12-18 2018-05-18 刘凤娟 一种用于治疗功能性胃肠病的5-羟色胺受体拮抗剂的合成方法
FI3814347T3 (fi) 2018-06-27 2023-06-12 Bristol Myers Squibb Co Naftyridinoniyhdisteitä, jotka ovat käyttökelpoisia t-solun aktivoijina
KR20210024586A (ko) 2018-06-27 2021-03-05 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2641602A (en) 1950-11-29 1953-06-09 Eastman Kodak Co 1, 8-dihydroxy-5-nitro-4-hydroxyethylphenyl aminoanthraquinone compounds
US3937708A (en) * 1971-06-07 1976-02-10 Boehringer Ingelheim Gmbh N-phenyl-imidazolidine-1-ones
US3975525A (en) * 1971-06-07 1976-08-17 Boehringer Ingelheim Gmbh N-[4'-Imidazolidinon-(2)-yl-phenethyl]-N'-pyridyl-piperazines and salts thereof
US3992537A (en) * 1971-06-07 1976-11-16 Boehringer Ingelheim Gmbh Pharmaceutical compositions containing an N-phenyl-imidazolidine-2-one and method of use
JPS5883677A (ja) 1981-11-11 1983-05-19 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
US4891275A (en) * 1982-10-29 1990-01-02 Norsk Hydro A.S. Aluminum shapes coated with brazing material and process of coating
JPS6354363A (ja) 1986-08-26 1988-03-08 Ss Pharmaceut Co Ltd キノリン誘導体
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4933447A (en) * 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US4891375A (en) * 1988-01-13 1990-01-02 Pfizer Inc. Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
JP2777159B2 (ja) 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
GB9300195D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
GB9308725D0 (en) * 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
BRPI9708389B8 (pt) * 1996-03-29 2015-12-08 Duphar Int Res compostos de piperazina e piperidina, composições farmacêuticas.
US5965560A (en) * 1996-04-30 1999-10-12 Warner-Lambert Company Substituted piperazines and piperidines as central nervous system agents
GB2312843A (en) 1996-05-07 1997-11-12 Merck & Co Inc Method of treating rheumatoid arthritis
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
DE69819266T2 (de) * 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
SK285198B6 (sk) 1997-10-27 2006-08-03 Neurosearch A/S Homopiperazínový derivát, farmaceutická kompozícia obsahujúca tento derivát a jeho použitie
CA2313125A1 (en) * 1997-12-12 1999-06-24 Laramie Mary Gaster Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
CN1158258C (zh) 1999-06-24 2004-07-21 东丽株式会社 肾上腺素能α1B受体拮抗药
ES2234683T3 (es) * 1999-11-05 2005-07-01 Smithkline Beecham Plc Derivados de isoquinolina y quinazolina con actividad combinada sobre los receptores 5ht1a, 5ht1b y 5ht1d.
CN1478092A (zh) 2000-10-26 2004-02-25 ʷ 苯并噁嗪酮衍生物及其制备和应用
CA2364211A1 (en) 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
GB0106419D0 (en) * 2001-03-15 2001-05-02 Smithkline Beecham Plc Novel compounds
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
GB0203804D0 (en) 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
MXPA05004273A (es) 2002-11-08 2005-10-18 Warner Lambert Co Derivados de fenilalquil y piridilalquil piperazina.
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
WO2005087745A1 (en) 2004-03-10 2005-09-22 Altana Pharma Ag Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
PE20060653A1 (es) 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1

Also Published As

Publication number Publication date
IS8304A (is) 2006-02-15
NO20060774L (no) 2006-04-06
ATE389637T1 (de) 2008-04-15
US7279481B2 (en) 2007-10-09
KR20060041242A (ko) 2006-05-11
JP2006528146A (ja) 2006-12-14
IS2744B (is) 2011-08-15
PL1646613T3 (pl) 2008-08-29
EP1876174A1 (en) 2008-01-09
MA27926A1 (fr) 2006-06-01
US20080280919A1 (en) 2008-11-13
US7459456B2 (en) 2008-12-02
CN100441571C (zh) 2008-12-10
SI1646613T1 (sl) 2008-08-31
US20060229312A1 (en) 2006-10-12
EP1646613A1 (en) 2006-04-19
BRPI0412695A (pt) 2006-10-03
CA2532452A1 (en) 2005-02-17
EP1876174B1 (en) 2009-11-11
US7592346B2 (en) 2009-09-22
US20090312546A1 (en) 2009-12-17
RU2006104993A (ru) 2006-08-10
WO2005014552A1 (en) 2005-02-17
RU2402533C2 (ru) 2010-10-27
MXPA06000716A (es) 2006-03-30
AU2004263268B2 (en) 2010-12-16
GB0316915D0 (en) 2003-08-20
EP2145622A1 (en) 2010-01-20
HK1089438A1 (en) 2006-12-01
ATE448205T1 (de) 2009-11-15
US20070167423A1 (en) 2007-07-19
PT1646613E (pt) 2008-06-19
DK1646613T3 (da) 2008-07-14
US7732600B2 (en) 2010-06-08
TW200521115A (en) 2005-07-01
AR046394A1 (es) 2005-12-07
US20100204273A1 (en) 2010-08-12
DE602004024141D1 (de) 2009-12-24
ES2302543T3 (es) 2008-07-16
CN1852896A (zh) 2006-10-25
DE602004012564T2 (de) 2009-04-30
ES2336148T3 (es) 2010-04-08
IL173036A0 (en) 2006-06-11
HRP20080226T3 (en) 2008-06-30
NZ544586A (en) 2009-05-31
AU2004263268A1 (en) 2005-02-17
EP1646613B1 (en) 2008-03-19
DE602004012564D1 (de) 2008-04-30

Similar Documents

Publication Publication Date Title
CY1107974T1 (el) Παραγωγα κινολινης και κιναζολινης εχοντα συναφεια προς τους υποδοχεις τυπου 5ht1
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
ATE450533T1 (de) Carboxamidderivate
ATE324371T1 (de) N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten
DE60140814D1 (de) N-phenyl-2-pyrimidine-amine derivatives
SE0401971D0 (sv) Piperidne derivatives
CY1111871T1 (el) Υποκατεστημενα βενζιμιδαζολια και μεθοδοι παρασκευης
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
TW200800946A (en) Substituted piperazines as metabotropic glutamate receptor antagonists
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
CY1106544T1 (el) Μεθοδος συνθεσεως υπερινδοπριλης και τα φαρμακευτικως αποδεκτα αλατα αυτης
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CY1113733T1 (el) Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DE60231426D1 (de) Solubilisierte topoisomerase-gift-mittel
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BRPI0517734A (pt) derivados de 1-[(6,7-alcoxiquinoxalinil substituìdo) aminocarbonil]-4- (hetero) arilpiperazina
ATE390923T1 (de) Topoisomerase-giftmittel
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200510312A (en) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
DE602005010725D1 (de) Indolin-2-one-pyridin-derivate, herstellung und therapeutische verwendung dafür
SE0301442D0 (sv) Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
SE0402763D0 (sv) Nitro indazole derivatives